Bicocca Open Archive

Logo unimib boa
LUPPI, FABRIZIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.262
AS - Asia 13.402
EU - Europa 7.237
SA - Sud America 2.107
AF - Africa 321
OC - Oceania 27
Continente sconosciuto - Info sul continente non disponibili 8
Totale 38.364
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.842
SG - Singapore 4.645
VN - Vietnam 2.664
CN - Cina 2.251
HK - Hong Kong 1.978
IT - Italia 1.713
BR - Brasile 1.604
RU - Federazione Russa 1.485
IE - Irlanda 932
DE - Germania 787
SE - Svezia 577
FR - Francia 404
GB - Regno Unito 393
IN - India 336
ID - Indonesia 242
CA - Canada 216
UA - Ucraina 216
BD - Bangladesh 197
AR - Argentina 196
FI - Finlandia 180
KR - Corea 176
TR - Turchia 141
ZA - Sudafrica 129
MX - Messico 121
NL - Olanda 110
IQ - Iraq 109
JP - Giappone 105
PK - Pakistan 105
AT - Austria 78
EC - Ecuador 73
ES - Italia 71
PL - Polonia 71
SA - Arabia Saudita 69
UZ - Uzbekistan 65
CO - Colombia 64
PH - Filippine 55
MA - Marocco 44
CH - Svizzera 38
PY - Paraguay 36
CL - Cile 35
VE - Venezuela 34
BE - Belgio 30
PE - Perù 29
DK - Danimarca 28
EG - Egitto 28
MY - Malesia 28
KE - Kenya 26
AE - Emirati Arabi Uniti 24
JO - Giordania 24
TN - Tunisia 24
TW - Taiwan 23
AU - Australia 22
UY - Uruguay 19
CZ - Repubblica Ceca 18
JM - Giamaica 18
PT - Portogallo 17
TH - Thailandia 17
DZ - Algeria 16
NP - Nepal 14
AZ - Azerbaigian 13
BO - Bolivia 13
DO - Repubblica Dominicana 13
IL - Israele 13
LT - Lituania 13
RO - Romania 12
ET - Etiopia 11
HN - Honduras 11
KZ - Kazakistan 10
OM - Oman 10
PS - Palestinian Territory 10
SN - Senegal 10
AL - Albania 9
KG - Kirghizistan 9
CR - Costa Rica 8
LB - Libano 8
BY - Bielorussia 7
IR - Iran 7
MN - Mongolia 7
NG - Nigeria 7
RS - Serbia 7
BB - Barbados 6
BG - Bulgaria 6
BH - Bahrain 6
GE - Georgia 6
GR - Grecia 6
HU - Ungheria 6
LV - Lettonia 5
NI - Nicaragua 5
NZ - Nuova Zelanda 5
PA - Panama 5
QA - Qatar 5
TT - Trinidad e Tobago 5
XK - ???statistics.table.value.countryCode.XK??? 5
CI - Costa d'Avorio 4
HR - Croazia 4
KH - Cambogia 4
LY - Libia 4
MT - Malta 4
MU - Mauritius 4
SV - El Salvador 4
Totale 38.299
Salva come PNG Salva come JPEG
Città #
Singapore 2.672
Hong Kong 1.948
Ann Arbor 1.515
Ashburn 1.346
Fairfield 1.223
San Jose 1.023
Dublin 912
Ho Chi Minh City 827
Hanoi 653
Wilmington 605
Woodbridge 518
Seattle 513
Frankfurt am Main 509
New York 476
Chandler 474
Houston 469
Milan 418
Dallas 414
Cambridge 390
Santa Clara 379
Chicago 370
Princeton 370
The Dalles 320
Beijing 309
Los Angeles 277
Hefei 275
Dearborn 272
Lauterbourg 214
Jakarta 182
Moscow 169
Seoul 164
Altamura 160
Nanjing 158
São Paulo 157
Jacksonville 152
Lawrence 139
Council Bluffs 129
Buffalo 124
Helsinki 119
Rome 107
Haiphong 103
Shanghai 103
Da Nang 94
Munich 87
Ottawa 80
San Diego 80
London 79
Boardman 78
Orem 77
Johannesburg 66
Andover 65
Tokyo 65
Guangzhou 63
Nuremberg 63
Tashkent 59
Rio de Janeiro 57
Warsaw 55
Toronto 49
Dong Ket 46
Hải Dương 46
Shenyang 46
Vienna 44
Biên Hòa 43
Mexico City 42
Hebei 41
Ha Long 40
Can Tho 39
Chennai 39
Montreal 39
Stockholm 39
Denver 38
Atlanta 37
Lappeenranta 37
Baghdad 36
Brasília 36
Monza 36
Salt Lake City 36
Fremont 35
Nanchang 35
Amsterdam 34
Dhaka 34
Phoenix 34
Ninh Bình 33
Quận Bình Thạnh 32
Thái Nguyên 32
Zurich 31
Bologna 30
Jinan 30
Bắc Ninh 29
Changsha 29
Poplar 29
Mumbai 28
Lahore 27
Porto Alegre 27
Ankara 26
Brooklyn 26
Elk Grove Village 26
Jiaxing 26
Naples 26
New Delhi 26
Totale 24.219
Salva come PNG Salva come JPEG
Nome #
Percent Predicted vs. Absolute Six-Minute Walk Distance as Predictors of Lung Transplant-Free Survival in Fibrosing Interstitial Lung Diseases 504
The ‘Liaisons dangereuses’ Between Lung Cancer and Interstitial Lung Diseases: A Focus on Acute Exacerbation 487
Diagnostic delay in bronchiectasis: an Italian perspective 434
Progressive fibrosing interstitial lung diseases: prevalence and characterization in two Italian referral centers 425
Early referral to palliative care services in patients with IPF: A tool to take a step forward 384
Healthcare costs and resources utilization in children with difficult-to-control asthma treated with biologic therapies: A population-based cohort study 363
What remains of long COVID after four years from hospitalization for severe COVID pneumonia 356
Use of 6-minute walk distance to predict lung transplant-free survival in fibrosing non-IPF interstitial lung diseases 347
Rehospitalization for pneumonia after first pneumonia admission: Incidence and predictors in a population-based cohort study 346
One-year pulmonary impairment after severe COVID-19: a prospective, multicenter follow-up study 345
Two-year cardio-pulmonary follow-up after severe COVID-19: a prospective study 343
The prognostic role of Gender-Age-Physiology system in idiopathic pulmonary fibrosis patients treated with pirfenidone 338
Interstitial Pneumonia with Autoimmune Features: Why Rheumatologist-Pulmonologist Collaboration Is Essential 331
Idiopathic pulmonary fibrosis mortality in the Italian epicenter of COVID-19 pandemic 322
A Real-Life Multicenter National Study on Nintedanib in Severe Idiopathic Pulmonary Fibrosis 296
Functional Progression in Patients with Interstitial Lung Disease Resulted Positive to Antisynthetase Antibodies: A Multicenter, Retrospective Analysis 296
Clinical Characteristics of Anti-synthetase Syndrome: Analysis From the Classification Criteria for Anti-Synthetase Syndrome Project 293
Non-tuberculous mycobacteria pulmonary disease: an integrated approach beyond antibiotics 288
Nutritional assessment in idiopathic pulmonary fibrosis: a prospective multicentre study 288
Economic impact of anti-IL-5 agents in patients with severe eosinophilic asthma: A population-based cohort study 284
Efficacy of pirfenidone for idiopathic pulmonary fibrosis: An Italian real life study 284
Janus-faced amiodarone-induced pneumopathy 280
Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers? 271
Diagnostic accuracy of a velcro sound detector (VECTOR) for interstitial lung disease in rheumatoid arthritis patients: The InSPIRAtE validation study (INterStitial pneumonia in rheumatoid ArThritis with an electronic device) 269
Effectiveness and economic impact of Dupilumab in asthma: a population-based cohort study 268
Six-Month Pulmonary Impairment after Severe COVID-19: A Prospective, Multicentre Follow-Up Study 266
Differences between acute exacerbations of idiopathic pulmonary fibrosis and other interstitial lung diseases 261
A multidisciplinary approach to screen the post-COVID-19 conditions 260
Structured reporting for fibrosing lung disease: a model shared by radiologist and pulmonologist 253
Short-term Evolution of Nutritional Status in Patients with Idiopathic Pulmonary Fibrosis 240
The impact of COVID-19 infection on idiopathic pulmonary fibrosis mortality: a systematic review and meta-analysis 238
Therapeutic Management of Bronchiectasis in Children and Adolescents: A Concise Narrative Review 237
Cigarette smoke extract (CSE) induces clusterion expression in human lung fibroblasts. 237
Molecular biomarkers in idiopathic pulmonary fibrosis: State of the art and future directions 235
Clinical course of IPF in Italian patients during 12 months of observation: results from the FIBRONET observational study 234
Cigarette smoke upregulates clusterin expression and apoptosis in human bronchial epithelial cells 233
The role of chest CT in deciphering interstitial lung involvement: systemic sclerosis versus COVID-19 233
Acute exacerbation of interstitial lung diseases secondary to systemic rheumatic diseases: A prospective study and review of the literature 232
Pirfenidone in real life: A retrospective observational multicentre study in Italian patients with idiopathic pulmonary fibrosis 231
Feasibility of CPAP application and variables related to worsening of respiratory failure in pregnant women with SARS-CoV-2 pneumonia: Experience of a tertiary care centre 230
Healthcare costs and resource utilisation in bronchiectasis, asthma and COPD 227
Interstiziopatia polmonare non classificabile o secondaria a connettivite indifferenziata. importanza e difficoltà di una diagnosi differenziale 226
Antifibrotic treatment response and prognostic predictors in patients with idiopathic pulmonary fibrosis and exposed to occupational dust 224
Impact of N-acetyl-L-cysteine on SARS-CoV-2 pneumonia and its sequelae: results from a large cohort study 223
What patients with Idiopathic Pulmonary Fibrosis and caregivers want - Filling the currents gaps with patient reported outcomes and experience measures 222
Predictive value of isolated DLCO reduction in systemic sclerosis patients without cardio-pulmonary involvement at baseline 219
Characteristics of long COVID after two years of follow-up in a previously hospitalized population 213
"Velcro-type" crackles predict specific radiologic features of fibrotic interstitial lung disease 211
Cardiovascular Structural and Functional Parameters in Idiopathic Pulmonary Fibrosis at Disease Diagnosis 210
Progression and prognosis of interstitial pneumonia with autoimmune features: a longitudinal, prospective, multi-centre study 209
Clinical differences in sarcoidosis patients with and without lymphoma: A single-centre retrospective cohort analysis 208
Feasibility and clinical impact of a portable bi-level ventilation device in patients with severe chronic obstructive pulmonary disease and exertional dyspnea: preliminary results from a clinical series 208
Pretreatment rate of decay in forced vital capacity predicts long-term response to pirfenidone in patients with idiopathic pulmonary fibrosis 204
Sarcopenia in idiopathic pulmonary fibrosis: a prospective study exploring prevalence, associated factors and diagnostic approach 203
Nintedanib and sildenafil in patients with idiopathic pulmonary fibrosis and right heart dysfunction: A prespecified subgroup analysis of a double-blind randomized clinical trial (instage) 201
Evaluation of preoperative cardiopulmonary reserve and surgical risk of patients undergoing lung cancer resection 200
Sleep-Disordered Breathing and Chronic Respiratory Infections: A Narrative Review in Adult and Pediatric Population 198
Idiopathic interstitial pneumonia in a patient with von Hippel-Lindau syndrome: a first case 197
Interstitial pneumonia with autoimmune features: A single center prospective follow-up study 197
Diagnosis of asthma and copd 196
Questionnaires May Help Pulmonologists for Referral of Patients With IPF to a Holistic Approach 193
Real-life comparison of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis: A 24-month assessment 191
Frailty and long-COVID: is COVID-19 responsible for a transition in frailty status among older adults who survived hospitalization for COVID-19? 189
Best supportive care for idiopathic pulmonary fibrosis: Current gaps and future directions 189
Intravenous methylprednisolone pulses in hospitalised patients with severe COVID-19 pneumonia, A double-blind, randomised, placebo-controlled trial 188
Acute exacerbation of idiopathic pulmonary fibrosis: a clinical review 184
Subclinical liver fibrosis in patients with idiopathic pulmonary fibrosis 184
Alteration of Lipid Metabolism in Patients with IPF and Its Association with Disease Severity and Prognosis: A Case–Control Study 182
Cystic lung in sarcoidosis: Clinico-radiologic characteristic and evolution 180
Treatment of acute exacerbation in interstitial lung disease secondary to autoimmune rheumatic diseases: More questions than answers 180
Effectiveness of pulmonary rehabilitation in patients with interstitial lung disease of different etiology: A multicenter prospective study 180
Acute exacerbation of idiopathic pulmonary fibrosis: Lessons learned from acute respiratory distress syndrome? 180
Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Lights and Shadows 180
Multidisciplinary approach to systemic diseases: benefits for diagnosis and management of complex disorders 178
Digital health technologies for improving the management of people with chronic obstructive pulmonary disease 177
Rheumatoid arthritis extra-articular lung disease: new insights on pathogenesis and experimental drugs 175
Ventilatory support and mechanical properties of the fibrotic lung acting as a “squishy ball” 175
Clinical Impact of Vaping 174
Prevalence and characterization of non-sicca onset primary Sjögren syndrome with interstitial lung involvement 170
Interstitial pneumonitis with autoimmune features (IPAF): A work in progress 170
The Multiple Components of COPD 170
Immune-Checkpoint-Inhibitor-Related Lung Toxicity: A Multicentre Real-Life Retrospective Portrait from Six Italian Centres 169
Management of fixed airflow limitation caused by asthma or chronic obstructive pulmonary disease 169
Interstitial pneumonia associated with autoimmune diseases: a possible mimicker of SARS-CoV-2 pneumonia 169
Healthcare utilisation and costs in the diagnosis and treatment of progressive-fibrosing interstitial lung diseases 167
High serum levels of silica nanoparticles in systemic sclerosis patients with occupational exposure: Possible pathogenetic role in disease phenotypes 167
The usual Interstitial pneumonia pattern in autoimmune rheumatic diseases 164
Pulse cyclophosphamide decreases sympathetic postganglionic activity, controls alveolitis, and normalizes vascular tone dysfunction (Raynaud's phenomenon) in a case of early systemic sclerosis 164
Analysis of pulmonary sounds for the diagnosis of interstitial lung diseases secondary to rheumatoid arthritis 163
Effects of cigarette smoke condensate on proliferation and wound closure of bronchial epithelial cells in vitro: role of glutathione 162
Clinical performance of a commercial real-time PCR assay for Aspergillus DNA detection in serum samples from high-risk patients: comparison with a galactomannan enzyme immunoassay 161
Evaluation of serum (1 → 3)-β-d-glucan clinical performance: kinetic assessment, comparison with galactomannan and evaluation of confounding factors 161
Guiding ILD management in systemic autoimmune rheumatic diseases 160
Management of Idiopathic Pulmonary Fibrosis 160
Clinical spectrum time course in non-Asian patients positive for anti-MDA5 antibodies 160
Diagnostic Management of Pediatric Bronchiectasis: A Literature Review and Clinical Examples 159
Performance of tests for latent tuberculosis in different groups of immunocompromised patients 158
Occurrence of idiopathic pulmonary fibrosis during immunosuppressive treatment: A case report 157
Corticosteroid and immunomodulatory agents in idiopathic pulmonary fibrosis 157
Bronchiectasis as long-term complication of acute fire smoke inhalation? 156
Totale 23.130
Salva come PNG Salva come JPEG
Categoria #
all - tutte 135.266
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 135.266
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021360 0 0 0 0 0 0 0 0 0 0 155 205
2021/20221.845 154 208 190 193 90 120 84 124 98 95 160 329
2022/20232.726 417 725 264 172 169 468 38 134 166 24 84 65
2023/20242.467 55 66 93 76 330 607 547 85 281 33 35 259
2024/20257.621 400 1.168 430 326 609 308 546 218 687 1.115 586 1.228
2025/202617.563 2.499 1.593 1.480 2.077 1.812 1.010 2.647 1.029 1.685 1.508 223 0
Totale 39.427